The more upbeat forecast for 2020 is largely due to President Trump’s trade war easing with China and the stimulus from 49 central banks, including the Federal Reserve, that lowered interest rates in recent months. ...

A data point from the Federal Reserve, highlighted recently in a special report on housing by the Economist, underscores the differences between millennials’ financial trajectory and those of earlier generations: In 1990, baby boomers, whose ...

You can view the list here (last updated Jan. 17). The total annual cost of the Old-Age and Survivors Insurance Trust Fund (OASI), which pays retirement and survivor benefits, and the Disability Insurance Trust Fund ...

“We are not just waiting for businesses to come,” said County Executive Angela D. Alsobrooks (D), who was elected in 2018. “We are going out, beating the bushes, to tell the story of Prince George’s ...

There’s a desire for change among global elites — but not nearly as far as Sens. Sanders (I-Vt.) and Warren (D-Mass.) want to go. The agenda at this year’s World Economic Forum is dominated by ...

“Mary Erdoes, JPMorgan Chase,” Trump said. “They just announced earnings, and they were incredible. …Will you say ‘thank you Mr. President’ at least? Huh? I made a lot of bankers look very good.” The exchange ...

“In fact, people are always doing impressive things,” the woman in the voice-over says. “So how come all these people who do wildly challenging things every day feel like they can’t do their taxes?” For ...

A technical recession occurs when output falls for six months, as it did from January to June last year. There were signs of a rebound after manufacturing production rose from July to September, but the ...

At the same time, Ross also warns friends to be skeptical of claims that the tariffs are triggering massive price increases on shoes, clothing, toys and more. Headlines last year proclaimed Trump’s tariffs could cost ...

Collins tearfully apologized to his family and his constituents, acknowledging that he tipped off his son to confidential information that a small Australian biotechnology company’s new therapy for multiple sclerosis had failed a critical clinical ...